loading page

Bacteriophage therapy for infections in CF
  • +2
  • Benjamin Chan,
  • Gail Stanley,
  • Mrinalini Modak,
  • Jon Koff,
  • Paul Turner
Benjamin Chan
Yale University

Corresponding Author:b.chan@yale.edu

Author Profile
Gail Stanley
Yale School of Medicine
Author Profile
Mrinalini Modak
Yale-New Haven Hospital
Author Profile
Jon Koff
Yale School of Medicine
Author Profile
Paul Turner
Yale University
Author Profile


Abstract. Pseudomonas aeruginosa and Staphylococcus aureus are bacterial pathogens frequently associated with pulmonary complications and disease progression in cystic fibrosis (CF) patients. However, these bacteria increasingly show multiple resistance to antibiotics, necessitating novel management strategies. One possibility is phage therapy, where lytic bacteriophages (phages; bacteria-specific viruses) are administered to kill target bacterial pathogens. Recent publication of case reports of phage-therapy treatment of antibiotic-resistant lung infections in CF has garnered significant attention. These cases exemplify the renewed interest in phage therapy, as an older concept that is newly updated to include rigorous collection and analysis of patient data to assess clinical benefit, while informing the development of clinical trials. As outcomes of these trials become public, the results will valuably gauge the potential usefulness of phage therapy to address the rise in antibiotic-resistant bacterial infections. In addition, we highlight the further need for basic research on accurately predicting the different responses of target bacterial pathogens when phages are administered alone, sequentially or as mixtures (cocktails), and whether within-cocktail interactions among phages hold consequences for the efficacy of phage therapy in patient treatment.
07 Aug 2020Submitted to Pediatric Pulmonology
07 Aug 2020Submission Checks Completed
07 Aug 2020Assigned to Editor
07 Aug 2020Reviewer(s) Assigned
17 Sep 2020Review(s) Completed, Editorial Evaluation Pending
18 Sep 2020Editorial Decision: Revise Major
28 Oct 20201st Revision Received
28 Oct 2020Submission Checks Completed
28 Oct 2020Assigned to Editor
28 Oct 2020Reviewer(s) Assigned
29 Oct 2020Review(s) Completed, Editorial Evaluation Pending
30 Oct 2020Editorial Decision: Accept
Feb 2021Published in Pediatric Pulmonology volume 56 issue S1. 10.1002/ppul.25190